{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:44:13Z","timestamp":1789926253957,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T00:00:00Z","timestamp":1444003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.eururo.2015.10.007","type":"journal-article","created":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T20:37:15Z","timestamp":1446237435000},"page":"720-727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND)"],"prefix":"10.1016","volume":"69","author":[{"given":"Claude","family":"Schulman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Cornel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vsevolod","family":"Matveev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teuvo L.","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Schraml","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Bensadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Warnack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Persad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Salagierski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"G\u00f3mez Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwina","family":"Baskin-Bey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2015.10.007_bib0120","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.10.007_bib0125","unstructured":"Mottet N, Bellmunt J, Briers E, et al. Guidelines on prostate cancer. European Association of Urology Web site. http:\/\/uroweb.org\/wp-content\/uploads\/09-Prostate-Cancer_LR.pdf. Accessed June 15, 2015."},{"key":"10.1016\/j.eururo.2015.10.007_bib0130","unstructured":"National Institute for Health and Care Excellence (NICE). NICE clinical guideline 175. NICE Web site. https:\/\/www.nice.org.uk\/guidance\/cg175. Updated 2014."},{"key":"10.1016\/j.eururo.2015.10.007_bib0135","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1200\/JCO.2012.46.5492","article-title":"Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials","volume":"31","author":"Niraula","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.10.007_bib0140","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/1097-0142(19861201)58:11<2546::AID-CNCR2820581131>3.0.CO;2-N","article-title":"Intermittent endocrine therapy for advanced prostate cancer","volume":"58","author":"Klotz","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2015.10.007_bib0145","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.juro.2012.01.122","article-title":"The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer","volume":"187","author":"Salonen","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.10.007_bib0150","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.eururo.2013.04.020","article-title":"Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials","volume":"64","author":"Sciarra","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.10.007_bib0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2490-14-9","article-title":"Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis","volume":"14","author":"Botrel","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.eururo.2015.10.007_bib0160","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/bju.12626","article-title":"Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?","volume":"114","author":"Wolff","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2015.10.007_bib0165","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2015.10.007_bib0170","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.ejca.2008.07.030","article-title":"An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer","volume":"44","author":"van Andel","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2015.10.007_bib0175","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3816\/CGC.2002.n.018","article-title":"Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial","volume":"1","author":"de Leval","year":"2002","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.eururo.2015.10.007_bib0180","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2015.10.007_bib0185","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2015.10.007_bib0190","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.eururo.2008.02.024","article-title":"Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study","volume":"54","author":"Irani","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.10.007_bib0195","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1464-410X.2012.11120.x","article-title":"Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial","volume":"110","author":"Mottet","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2015.10.007_bib0200","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2012.07.040","article-title":"Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects","volume":"63","author":"Salonen","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.10.007_bib0205","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00345-013-1206-0","article-title":"Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial","volume":"32","author":"Verhagen","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2015.10.007_bib0210","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/pcan.2012.12","article-title":"Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy","volume":"15","author":"Tunn","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2015.10.007_bib0215","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.eururo.2013.03.055","article-title":"Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group","volume":"66","author":"Calais da Silva","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.10.007_bib0220","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.eururo.2014.05.037","article-title":"Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer","volume":"66","author":"Boccon-Gibod","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.10.007_bib0225","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.eursup.2009.07.005","article-title":"Intermittent hormone therapy: what is its place in clinical practice?","volume":"8","author":"Schulman","year":"2009","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2015.10.007_bib0230","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","article-title":"Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916","volume":"27","author":"Hussain","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228381500977X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228381500977X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T05:24:58Z","timestamp":1537248298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228381500977X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S030228381500977X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2015.10.007","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND)","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2015.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association of Urology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}